Wall Street Zen Upgrades Sensei Biotherapeutics (NASDAQ:FTH) to Sell

Sensei Biotherapeutics (NASDAQ:FTH) was upgraded by equities researchers at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research report issued on Saturday.

A number of other equities research analysts have also recently weighed in on FTH. Zacks Research raised Sensei Biotherapeutics to a “hold” rating in a research note on Tuesday, April 21st. Robert W. Baird initiated coverage on Sensei Biotherapeutics in a research note on Friday, June 26th. They set an “outperform” rating and a $57.00 target price on the stock. BTIG Research restated a “buy” rating and set a $55.00 target price on shares of Sensei Biotherapeutics in a report on Thursday, July 16th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Sensei Biotherapeutics in a research report on Thursday, June 4th. Finally, Leerink Partners initiated coverage on shares of Sensei Biotherapeutics in a research note on Monday, April 20th. They set an “outperform” rating and a $50.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $54.90.

Sensei Biotherapeutics Price Performance

Shares of FTH opened at $24.39 on Friday. Sensei Biotherapeutics has a 1-year low of $7.20 and a 1-year high of $37.90. The stock has a market cap of $32.73 million, a price-to-earnings ratio of -0.17 and a beta of -0.25.

Sensei Biotherapeutics (NASDAQ:FTH) last announced its earnings results on Friday, May 15th. The company reported ($131.45) earnings per share (EPS) for the quarter. As a group, equities research analysts predict that Sensei Biotherapeutics will post -13.18 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Sensei Biotherapeutics news, major shareholder James Peyer sold 25,000 shares of the company’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $20.02, for a total transaction of $500,500.00. Following the sale, the insider owned 130,142 shares in the company, valued at $2,605,442.84. This represents a 16.11% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Brian C. Stephenson purchased 9,391 shares of Sensei Biotherapeutics stock in a transaction on Wednesday, June 24th. The stock was bought at an average cost of $26.13 per share, for a total transaction of $245,386.83. Following the transaction, the chief financial officer directly owned 26,804 shares in the company, valued at $700,388.52. This represents a 53.93% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased 49,494 shares of company stock valued at $1,188,822 in the last three months. 7.00% of the stock is owned by corporate insiders.

Institutional Trading of Sensei Biotherapeutics

A number of large investors have recently made changes to their positions in FTH. Vivo Capital LLC acquired a new position in Sensei Biotherapeutics during the 1st quarter worth approximately $22,758,000. Stempoint Capital LP acquired a new stake in shares of Sensei Biotherapeutics in the 1st quarter valued at $4,188,000. Bank of America Corp DE raised its holdings in shares of Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after purchasing an additional 32,719 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its position in shares of Sensei Biotherapeutics by 178.2% during the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock worth $1,010,000 after purchasing an additional 20,525 shares during the last quarter. 10.50% of the stock is currently owned by hedge funds and other institutional investors.

Sensei Biotherapeutics News Summary

Here are the key news stories impacting Sensei Biotherapeutics this week:

• Positive Sentiment: HC Wainwright significantly improved its long-term outlook. The analyst raised projected EPS for fiscal 2026 to a loss of $13.54 from $16.61, fiscal 2027 to a loss of $2.68 from $3.72, fiscal 2028 to a loss of $2.37 from $3.19, fiscal 2029 to a loss of $2.25 from $3.16, and fiscal 2030 to a loss of $2.54 from $3.07. Quarterly loss estimates for late 2026 and 2027 were also reduced. The firm maintained a Buy rating and a $60 price target, implying substantial upside from recent trading levels. HC Wainwright estimate revisions
• Positive Sentiment: JonesTrading initiated coverage of Sensei Biotherapeutics. New analyst coverage can increase investor attention and potentially improve liquidity, although the report’s rating and price target were not provided. JonesTrading Begins Coverage on Sensei Biotherapeutics
• Neutral Sentiment: Faeth announced inducement grants to two new employees. The awards cover options to purchase 11,000 shares under the company’s 2026 Inducement Plan. Hiring may support corporate development, but the grants could modestly dilute existing shareholders and are unlikely to materially affect the stock by themselves. Faeth Therapeutics Announces Inducement Grants

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.